227. オスラー病 [臨床試験数:49,薬物数:69(DrugBank:21),標的遺伝子数:23,標的パスウェイ数:132

Searched query = "Osler disease", "Hereditary hemorrhagic telangiectasia", "Osler-Weber-Rendu disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
14 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04404881May 202022/5/2020Bevacizumab In Hereditary Hemorrhagic TelangiectasiaA Phase 2 Study of Bevacizumab for Chronic Bleeding and Iron Deficiency Anemia in Hereditary Hemorrhagic TelangiectasiaHereditary Hemorrhagic TelangiectasiaDrug: BevacizumabHanny Al-Samkari, MDNULLNot yet recruiting18 YearsN/AAll20Phase 2United States
2EUCTR2017-001031-39-FR19/05/201719/06/2020BABH Study: Efficacy and safety of bevacizumab on severe bleedings associated with Hemorrhagic Hereditary Telangiectasia (HHT)BABH Study: Efficacy and safety of bevacizumab on severe bleedings associated with Hemorrhagic Hereditary Telangiectasia (HHT). A National, randomized multicenter phase III study. - BABH Hemorrhagic Hereditary Telangiectasia
MedDRA version: 20.0Level: LLTClassification code 10031132Term: Osler-Weber-Rendu diseaseSystem Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: AVASTIN
Product Name: BEVACIZUMAB
INN or Proposed INN: BEVACIZUMAB
Hospices Civils de LyonNULLNot RecruitingFemale: yes
Male: yes
24Phase 3France
3NCT02157987December 15, 20144/6/2014Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective DoseTreatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective DoseTelangiectasia, Hereditary HemorrhagicDrug: bevacuzimab sprayUniversity Hospital, CaenNULLRecruiting18 Years70 YearsAll30Phase 1/Phase 2France
4NCT02389959August 4, 201411/3/2015Intranasal Bevacizumab for HHT-Related EpistaxisIntranasal Bevacizumab for HHT-Related EpistaxisHHT;Hereditary Hemorrhagic Telangiectasia;Epistaxis;Nose Bleeds;Nasal BleedingDrug: Bevacizumab;Drug: Placebo (Saline)Stanford UniversityNULLCompleted18 YearsN/AAll40Phase 4United States
5NCT02106520April 20141/4/2014Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic Telangiectasia;EpistaxisDrug: Bevacizumab;Drug: placeboHospices Civils de LyonNULLTerminated18 YearsN/ABoth80Phase 2/Phase 3France
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2013-004204-19-FR26/02/201416/06/2015Efficacité du bevacizumab en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-OslerEfficacité du bevacizumab en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-Osler - ALEGORI Rendu-Osler disease
MedDRA version: 18.0Level: LLTClassification code 10031132Term: Osler-Weber-Rendu diseaseSystem Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Avastin
Product Name: Avastin
INN or Proposed INN: BEVACIZUMAB
Hospices Civils de LyonNULLNot RecruitingFemale: yes
Male: yes
France
7NCT01507480October 20116/12/2011The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic TelangiectasiaThe ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia.Hemorrhagic Hereditary TelangiectasiaDrug: BevacizumabHospices Civils de LyonNULLCompleted18 YearsN/ABoth42Phase 1France
8NCT01408030August 20111/8/2011North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)North American Study of Epistaxis in HHT (NOSE)Telangiectasia, Hereditary Hemorrhagic;EpistaxisDrug: Sterile saline;Drug: Bevacizumab;Drug: Estriol;Drug: Tranexamic AcidJames GossageHHT Foundation InternationalCompleted18 YearsN/AAll123Phase 2United States
9NCT01314274March 20119/3/2011Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)A Randomized Double Blind Placebo Controlled Trial of Intranasal Submucosal Bevacizumab in Hereditary Hemorrhagic TelangiectasiaHHT;Morbus Osler;EpistaxisDrug: Bevacizumab;Drug: NaClMedical University of ViennaNULLCompleted18 Years80 YearsBoth15Phase 2Austria
10EUCTR2009-018049-19-AT13/12/201023/11/2010A randomized double blind placebo controlled trial of intranasal submucosal bevacizumab in hereditary hemorrhagic telangiectasia - Bevazizumab in HHTA randomized double blind placebo controlled trial of intranasal submucosal bevacizumab in hereditary hemorrhagic telangiectasia - Bevazizumab in HHT epistaxisTrade Name: AVASTIN 25 mg/ml - Konzentrat zur Herstellung einer Infusionsloesung
INN or Proposed INN: BEVACIZUMAB
Trade Name: PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung
Product Name: PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung
Other descriptive name: SODIUM CHLORIDE
Medizinische Universität Wien,Univ.Klinik f.Hals-, Nasen- und OhrenkrankheitenNULLNot RecruitingFemale: yes
Male: yes
30Austria
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT01402531July 22, 201019/7/2011Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic Telangiectasia (HHT)Drug: Submucosal BevacizumabUniversity of California, San DiegoNULLCompleted18 YearsN/AAll10Phase 2United States
12NCT01397695June 200918/7/2011Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic Telangiectasia (HHT)Drug: BevacizumabUniversity of California, San DiegoNULLCompleted18 YearsN/AAll20Phase 2United States
13EUCTR2008-006755-44-FR15/01/200917/03/2009METAFORE : Maladie de Rendu-Osler : Etude de l’Efficacité et de la tolérance du Bevacizumab utilisé pour le traitement des formes hépatiques sévères. Etude de phase II - METAFOREMETAFORE : Maladie de Rendu-Osler : Etude de l’Efficacité et de la tolérance du Bevacizumab utilisé pour le traitement des formes hépatiques sévères. Etude de phase II - METAFORE Maladie de Rendu-Osler
MedDRA version: 9.1Level: LLTClassification code 10031132Term: Osler-Weber-Rendu disease
Trade Name: AVASTIN
Product Name: AVASTIN
INN or Proposed INN: BEVACIZUMAB
Other descriptive name: SUB16402MIG
HOSPICES CIVILS DE LYONNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2France
14EUCTR2010-020545-26-IT09/12/200810/09/2010BEVACIZUMAB, AN ANTI-ANGIOGENIC MONOCLONAL ANTIBODY EFFECTIVE FOR PREVENTION OF HEMORRHAGING IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT): POSSIBLE REGRESSION OF VISCERAL ARTERIOVENOUS MALFORMATIONS - NDBEVACIZUMAB, AN ANTI-ANGIOGENIC MONOCLONAL ANTIBODY EFFECTIVE FOR PREVENTION OF HEMORRHAGING IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT): POSSIBLE REGRESSION OF VISCERAL ARTERIOVENOUS MALFORMATIONS - ND HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
MedDRA version: 9.1Level: SOCClassification code 10005329
Trade Name: AVASTIN
INN or Proposed INN: Bevacizumab
Trade Name: AVASTIN
INN or Proposed INN: Bevacizumab
Trade Name: AVASTIN
INN or Proposed INN: Bevacizumab
AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALENULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy